Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Elimination of Specific miRNAs by Naked 14-nt sgRNAs

  • Masayuki Takahashi ,

    Contributed equally to this work with: Masayuki Takahashi, Reyad A. Elbarbary

    Affiliation Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan

  • Reyad A. Elbarbary ,

    Contributed equally to this work with: Masayuki Takahashi, Reyad A. Elbarbary

    Affiliation Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan

  • Mayumi Abe,

    Affiliation Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan

  • Mari Sato,

    Affiliation Department of Biochemistry and Molecular Biology, Hokkaido University Graduate School of Dental Medicine, Sapporo, Japan

  • Tetsuo Yoshida,

    Affiliation Biologics Research Laboratories, Kyowa Hakko Kirin Company Limited, Machida, Japan

  • Yoji Yamada,

    Affiliation Biologics Research Laboratories, Kyowa Hakko Kirin Company Limited, Machida, Japan

  • Masato Tamura,

    Affiliation Department of Biochemistry and Molecular Biology, Hokkaido University Graduate School of Dental Medicine, Sapporo, Japan

  • Masayuki Nashimoto

    mnashimoto@nupals.ac.jp

    Affiliation Department of Applied Life Sciences, Niigata University of Pharmacy and Applied Life Sciences, Niigata, Japan

Abstract

tRNase ZL-utilizing efficacious gene silencing (TRUE gene silencing) is a newly developed technology to suppress mammalian gene expression. TRUE gene silencing works on the basis of a unique enzymatic property of mammalian tRNase ZL, which is that it can recognize a pre-tRNA-like or micro-pre-tRNA-like complex formed between target RNA and artificial small guide RNA (sgRNA) and can cleave any target RNA at any desired site. There are four types of sgRNA, 5′-half-tRNA, RNA heptamer, hook RNA, and ∼14-nt linear RNA. Here we show that a 14-nt linear-type sgRNA against human miR-16 can guide tRNase ZL cleavage of miR-16 in vitro and can downregulate the miR-16 level in HEK293 cells. We also demonstrate that the 14-nt sgRNA can be efficiently taken up without any transfection reagents by living cells and can exist stably in there for at least 24 hours. The naked 14-nt sgRNA significantly reduced the miR-16 level in HEK293 and HL60 cells. Three other naked 14-nt sgRNAs against miR-142-3p, miR-206, and miR-19a/b are also shown to downregulate the respective miRNA levels in various mammalian cell lines. Our observations suggest that in general we can eliminate a specific cellular miRNA at least by ∼50% by using a naked 14-nt sgRNA on the basis of TRUE gene silencing.

Introduction

tRNase ZL is a long form of tRNA 3′ processing endoribonuclease (tRNase Z, or 3′ tRNase) [1], [2]. In human cells, nuclear full-length tRNase ZL works on precursor tRNAs to process them by removing their 3′ trailer, whereas cytosolic Δ30 tRNase ZL appears to work on mRNAs to modulate gene expressions by cleaving them under the direction of cellular small noncoding RNAs such as 5′-half-tRNA and miRNA [3], [4]. It has been shown that cytosolic tRNase ZL modulates the PPM1F gene expression by cleaving its mRNA under the direction of 5′-half-tRNAGlu [3] and that miR-103 can downregulate gene expression through directing mRNA cleavage by cytosolic tRNase ZL [4]. The cytosolic tRNase ZL together with the small noncoding RNAs appears to form a broad gene regulatory network.

We have developed a technology for suppressing the expression of a target gene by modulating this gene regulatory network under the aegis of artificial small guide RNA (sgRNA) [5][9]. This technology works on the basis of a unique enzymatic property of mammalian tRNase ZL, which is that it can recognize a pre-tRNA-like or micro-pre-tRNA-like complex formed between target RNA and artificial sgRNA and can cleave any target RNA at any desired site [10][16]. There are four types of sgRNA, 5′-half-tRNA [11], RNA heptamer [12], hook RNA [15], and ∼14-nt linear RNA [16], and this technology is termed TRUE gene silencing after tRNase ZL-utilizing efficacious gene silencing. The efficacy of TRUE gene silencing can become comparable to that of the RNA interference [7] and can surpass it in some cases [8].

miRNAs play important regulatory roles in many cellular processes, and their dysfunction appears to cause many diseases including cancer and heart disease [17]. It has been shown in human cells that miR-15a and miR-16 work as tumor suppressors, while miR-17-92, miR-19a/b, miR-21, and miR-181a/b are oncogenic [18][20]. miR-122, which is abundant in liver cells, has been shown to be a regulator of fatty-acid metabolism [21], and its expression appears to be essential for replication of hepatitis C virus [22]. Thus we can expect that elimination of specific miRNAs in the cells would lead to cures of some diseases. Indeed, downregulation of the miR-19 or miR-181 level in myeloma cells by an antisense nucleic acid has been demonstrated to suppress tumor growth in nude mice [20]. And oligonucleotides against miR-122 can reduce a blood cholesterol level [21] and can also suppress the replication of hepatitis C virus [22].

In this paper, we investigated if TRUE gene silencing can eliminate specific miRNAs from human cells. And we show that human tRNase ZL can cleave miRNA under the direction of 14-nt linear-type sgRNA in vitro and that naked 14-nt sgRNA can significantly downregulate miRNA expression in vivo.

Materials and Methods

RNA/DNA Synthesis

The following eleven 5′- and/or 3′-phosphorylated RNAs with full 2′-O-methyl modifications, 3′-Alexa-568-labeled 5′-phosphorylated sgR16(1–14) with full 2′-O-methyl modifications, 3′-FITC-labeled 5′-phosphorylated sgRNA14 with full 2′-O-methyl modifications, and 5′-FITC-labeled miR-16 were chemically synthesized by Nippon Bioservice: sgR16(1–14), 5′-pUUUACGUGCUGCUA(p)-3′; sgR16(9–22), 5′-pCGCCAAUAUUUACG-3′; sgR16(1–22), 5′-pCGCCAAUAUUUACGUGCUGCUA(p)-3′; sgR16(1–12), 5′-pUACGUGCUGCUA-3′; sgR16(6–17), 5′-pAUAUUUACGUGC-3′; sgR16(4–17), 5′-pAUAUUUACGUGCUG-3′; sgR16(4–15), 5′-pAUUUACGUGCUG-3′; sgR142(1–14), 5′-pUAGGAAACACUACAp-3′; sgR142(1–23), 5′-pUCCAUAAAGUAGGAAACACUACAp-3′; sgR206(1–14), 5′-pUUCCUUACAUUCCAp-3′; sgR19(1–14), 5′-pCAUGGAUUUGCACAp-3′; sgRNA14, 5′-pGGGGGCGGCCCCCG-3′; miR-16, 5′-UAGCAGCACGUAAAUAUUGGCG-3′.

The following DNA probes and primers were obtained from Hokkaido System Science: miR-16 probe, 5′-CGCCAATATTTACGTGCTGCTA-3′; 5S rRNA probe, 5′-AAGCCTACAGCACCCGGTATT-3′; miR-16 reverse transcription primer, 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACCGCCAA -3′; miR-16 forward primer, 5′-CGCGCTAGCAGCACGTAAAT-3′; miR-16 and miR-19a/b reverse primer, 5′-GTGCAGGGTCCGAGGT-3′; miR-19a/b reverse transcription primer, 5′-GTCGTATCCAGTGCAGGGTCCGAGGTATTCGCACTGGATACGACTCAGTT-3′; miR-19a/b forward primer, 5′-CGCGCTGTGCAAATCTATGC-3′; 5S rRNA forward primer, 5′-GTCTACGGCCATACCACCCTG-3′; 5S rRNA reverse primer, 5′-AAGCCTACAGCACCCGGTATT-3′; Bcl-2 mRNA forward primer, 5′-GCCCTCACTGGCCTCCTCCA-3′; Bcl-2 mRNA reverse primer, 5′-GTGACAGGCCCAGCCACACC-3′; β-actin mRNA forward primer, 5′-CTGGAACGGTGAAGGTGACA-3′; β-actin mRNA reverse primer, 5′-AAGGGACTTCCTGTAACAACGCA-3′. The siRNA targeting the human tRNase ZL mRNA was obtained from Qiagen: sense, r(GACUCCGAGUCGAAUGAAA)d(TT); antisense, r(UUUCAUUCGACUCGGAGUC)d(TG). Silencer Negative Control No. 1 siRNA (#4611; Ambion) was used as a scramble siRNA.

In vitro RNA Cleavage Assay

In vitro RNA cleavage assays for the FITC-labeled miR-16 (2 pmol) were carried out at 37°C in the presence of the unlabeled sgRNAs (20 pmol) using histidine-tagged human Δ30 tRNase ZL (50 ng) in a mixture (6 µl) containing 10 mM Tris-HCl (pH 7.5), and 3.3 mM MgCl2. After resolution of the reaction products on a 15% polyacrylamide-8 M urea gel, the gel was analyzed with a Typhoon 9210 (GE Healthcare).

Cell Culture and Transfection

Various mammalian cells, HEK293 [23], HeLa [24], Jurkat [25], HL60 [26], DAUDI (obtained from RIKEN BioResource Center, Tsukuba, Japan), C2C12 [27], and RPMI-8226 [28], were cultured in RPMI-1640 or DME media (Wako) supplemented with 10% fetal bovine serum (FBS; MP Biomedicals) and 1% penicillin-streptomycin (Invitrogen) at 37°C in 5% CO2 humidified incubator.

HEK293 cells were transfected with sgRNA or with sgRNA and scramble or anti-tRNase-ZL siRNA using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol, and cultured for further 42 hours.

Northern Analysis

Total RNA was extracted with ISOGEN. The RNA samples (10 µg) were separated by 15% polyacrylamide/8 M urea gel electrophoresis, and electrically transferred to a Hybond N+ membrane (GE Healthcare). The membrane was ultraviolet-crosslinked, probed with a 5′-32P-labeled deoxyoligonucleotide in a QuickHyb buffer (Stratagene) at 45°C, and analyzed with the Typhoon 9210.

Real-Time PCR

Total RNA was extracted from cells using ISOGEN. The cellular amounts of miR-16, miR-142-3p, and miR-206 were quantitated by a StepOne Real Time PCR System using TaqMan MicroRNA Assays and TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). The miR-16, miR-19a/b, Bcl-2 mRNA and β-actin mRNA levels were quantitated by real-time PCR using a LightCycler 480 SYBR Green I Kit (Roche).

Western Analysis

Whole cell extracts dissolved in a buffer (50 mM Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 100 mM dithiothreitol) were separated by SDS/7.5% polyacrylamide gel electrophoresis, and transferred to a nitrocellulose membrane. The membrane was probed with polyclonal antibodies raised to a human tRNase ZL peptide (amino acid 812–826) or a monoclonal antibody against human β-actin (Sigma) using the ECL Western Blotting Detection System (GE Healthcare).

Fluorescent Microscopic Analysis

HL60 and RPMI-8226 cells (5×104 cells/well) were cultured in 24-well plates in the absence and presence of 1 µM Alexa-568-labeled sgR16(1–14), and HEK293 cells (5×104 cells) were likewise in a fibronectin-coated chamber slide. After 24 hours, the cells were rinsed twice with 1×phosphate-buffered saline (PBS) and fixed with 4% paraformaldehyde in 1×PBS for 3 min. Hoechst 33342 (DOJINDO) was used to stain DNA, and the cells were analyzed with the fluorescent microscope system Axio Imager.M2 (Zeiss).

sgRNA Survivability Test

Human cells (0.8–1×105 cells/well) were cultured in a 24-well plate, and 24 hours after the addition of 1 µM of the 3′-Alexa-568-labeled sgR16(1–14) or the 3′-FITC-labeled sgRNA14 to the medium, the cells were harvested and washed four times with 1 ml of 1×PBS. Total RNA was extracted from the cells with ISOGEN, and separated on a 20% polyacrylamide-8 M urea gel. The gel was analyzed with the Typhoon 9210.

Statistical Analysis

Differences between control and experimental groups were evaluated by the Student’s t-test.

Results and Discussion

tRNase ZL can Cleave miR-16 under the Direction of a 14-nt sgRNA

To examine if tRNase ZL can cleave miRNA under the direction of sgRNA, we performed an in vitro tRNase ZL cleavage assay for human miR-16. A 14-nt linear-type sgRNA, sgR16(1–14), which is complementary to the 1st–14th nucleotides of miR-16, and a control 14-nt RNA, sgR16(9–22), which is complementary to 9th–22nd nucleotides of miR-16, were chemically synthesized as 2′-O-methyl RNA (Figure 1A). As expected, miR-16 was cleaved after the 16th A by tRNase ZL under the direction of sgR16(1–14), but not sgR16(9–22) (Figure 1B).

thumbnail
Figure 1. Downregulation of the miR-16 expression by TRUE gene silencing.

(A and E) Structures of the complexes of sgRNAs with human miR-16. An arrow indicates the tRNase ZL cleavage site. (B and F) In vitro tRNase ZL cleavage assays. 5′-fluorescein-labeled miR-16 was incubated with recombinant human Δ30 tRNase ZL in the absence or presence of sgRNA, which was phosphorylated at the 5′ end but not at the 3′ end. The cleavage products were analyzed on a denaturing 15% polyacrylamide gel. L, alkaline ladder of miR-16; I, input RNA. (C) Northern analysis for human miR-16. Total RNA was extracted from the HEK293 cells that were transfected with mock, 100 nM of sgR16(1–14), sgR16(9–23) or sgR16(1–23) without (left) or together with 100 nM of the anti-tRNase-ZL siRNA (right). sgR16(1–14), sgR16(9–23), and sgR16(1–23) were phosphorylated at the 5′ end but not at the 3′ end. The total RNA (10 µg) was separated on a denaturing 15% polyacrylamide gel. Bromophenol blue (∼10 nt) and xylene cyanol (∼35 nt) were used as size markers. (D) The same RNA samples as in C were analyzed by a StepOne Real Time PCR System. The miRNA levels are normalized against the RNU48 levels. Error bars indicate s.d. (n = 3). *, P<0.005.

https://doi.org/10.1371/journal.pone.0038496.g001

We also tested 4 more linear-type sgRNAs against miR-16 for their guiding ability. These sgRNAs, sgR16(1–12), sgR16(6–17), sgR16(4–17), and sgR16(4–15), are designed to be complementary to 12 or 14 nucleotides of miR-16 (Figure 1E,F). All these sgRNAs guided tRNase ZL cleavage of miR-16, albeit inefficiently compared with sgR16(1–14). The cleavages directed by sgR16(6–17), sgR16(4–17), and sgR16(4–15) occurred primarily after a nucleotide corresponding to the discriminator nucleotide, whereas those by sgR16(1–14) and sgR16(1–12) occurred primarily 1-nt downstream and 1-nt upstream, respectively. These cleavage site fluctuations have been previously described as a property of tRNase ZL [16], [29].

These results suggest that both the length and the binding site of sgRNA are important for its efficient guiding ability. We focused on 14-nt sgRNAs that are complementary to the 1st–14th nucleotides of miRNAs for the following in vivo analyses.

Downregulation of the miR-16 level by TRUE Gene Silencing

Next, we examined if sgR16(1–14) works as sgRNA against miR-16 in human cells. sgR16(1–14), sgR16(9–22), or the 22-nt antisense RNA sgR16(1–22) was transfected into HEK293 cells, and the cellular miR-16 level was analyzed by northern blotting and real-time PCR. sgR16(1–14) and sgR16(1–22) significantly downregulated the miR-16 level, whereas sgR16(9–22) did not at all (Figure 1C,D). We also carried out co-transfection experiments with siRNA against human tRNase ZL mRNA. The reduction in the miR-16 level by sgR16(1–14) was restored by downregulating the tRNase ZL expression, while the reduction by sgR16(1–22) was not affected (Figure 1C,D).

We performed similar experiments under slightly different conditions, in which 5′- and 3′-phosphorylated sgR16(1–14) and sgR16(1–22) were used, and also analyzed tRNase ZL levels by western blotting. In one set of the experiments, we obtained results similar to the above ones, but restoration of the miR-16 level reduction by downregulating the tRNase ZL expression was incomplete (Figure S1A). This may be due to incomplete elimination of tRNase ZL (Figure S1B) and/or due to a possible weak binding and sequestering effect of sgR16(1–14).

In another set of the experiments, in which a scramble siRNA was used as a control, we also obtained similar results (Figure 2). Together, these results suggest that tRNase ZL is responsible at least partly for the reduction by sgR16(1–14) but not by sgR16(1–22) and that TRUE gene silencing can downregulate the miRNA expression. The mechanism by which sgR16(1–22) acts on the miR-16 level would be through binding and sequestering [20][22].

thumbnail
Figure 2. tRNase ZL is responsible at least partly for the reduction in the miR-16 level by sgR16(1–14).

(A) Quantitation of the miR-16 level in HEK293 cells with a LightCycler 480 SYBR Green I Kit. The HEK293 cells were transfected with mock, 35 nM of sgR16(1–14) or sgR16(1–22) together with 50 nM of the scramble siRNA or the anti-tRNase-ZL siRNA. sgR16(1–14) and sgR16(1–22) were phosphorylated at both 5′ and 3′ ends. The miR-16 levels are normalized against the 5S rRNA levels. Error bars indicate s.d. (n = 3). *, P<0.001. (B) Western blot analysis. The tRNase ZL level under the above transfection conditions was analyzed. β-actin was used as a loading control.

https://doi.org/10.1371/journal.pone.0038496.g002

Naked Linear-type sgRNA can be Taken up by Living Cells

We investigated how efficiently linear-type sgRNA can be taken up by living cells without any transfection reagents and can downregulate the miRNA expression. HL60 cells were cultured in the presence of 1 µM of the naked 14-nt 3′-Alexa-568-labeled sgR16(1–14) and analyzed with a fluorescent microscope. This sgRNA was indeed efficiently taken up without any transfection reagents by HL60 cells (Figure 3A). RPMI-8226 and HEK293 cells also took up the naked sgRNA efficiently (Figure 3A). We also showed that another 14-nt RNA, sgRNA14, can be taken up nakedly by HeLa, HEK293, and Jurkat cells (Figure S2A,B and Text S1).

thumbnail
Figure 3. Naked linear-type sgRNA can be taken up by living cells.

(A) Microscopic images of HL60, RPMI-8226 and HEK293 cells. The cells were fixed and stained with Hoechst 3342, 24 hours after the cells were cultured in the absence or presence of 1 µM of the naked 3′-Alexa-568-labeled sgR16(1–14). (B and C) sgRNA survivability tests. The 3′-Alexa-568-labeled sgR16(1–14) was analyzed on a denaturing 20% polyacrylamide gel. The sgRNA recovered from inside the cells are shown, which took it up nakedly or with the aid of Lipofectamine 2000 (LF). The band denoted by an asterisk would correspond to a degradation product of sgR16(1–14). Standard, 3′-Alexa-568-labeled sgR16(1–14).

https://doi.org/10.1371/journal.pone.0038496.g003

Furthermore, we demonstrated by polyacrylamide gel analysis of total RNA from HL60, RPMI-8226, and HEK293 cells that at least a part of the taken-up sgR16(1–14) molecules exist stably for at least 24 hours in the cells (Figure 3B,C). And at least a part of sgRNA14 molecules were also stable for at least 24 hours in HeLa, HEK293, and Jurkat cells (Figure S2C). However, the amount of sgR16(1–14) recovered from HEK293 cells that took it up with the aid of a transfection reagent was much higher than that recovered from the cells that took it up nakedly (Figure 3C), suggesting that sgR16(1–14) can be taken up more easily and/or can exist more stably in the presence of the transfection reagent.

Reduction in the miR-16 Level by a Naked 14-nt sgRNA

We cultured HEK293 cells in the presence of 1 µM of naked sgR16(1–14), sgR16(9–22), or sgR16(1–22), and analyzed the cellular miR-16 level by real-time PCR. These RNAs were phosphorylated at the 5′ end but not at the 3′ end. While sgR16(9–22) and sgR16(1–22) did not reduce the miR-16 level at all, sgR16(1–14) significantly reduced the level to 58% (Figure 4A). These results contrast with those obtained with a transfection reagent, in which sgR16(1–22) almost completely eliminated cellular miR-16 (Figure 1D).

thumbnail
Figure 4. Reduction in the miR-16 level by a naked 14-nt sgRNA.

(A) Quantitation of the miR-16 level in HEK293 cells with a StepOne Real Time PCR System. Total RNA was extracted from the HEK293 cells that were cultured for 24 hours in the absence or presence of sgR16(1–14), sgR16(9–22), or sgR16(1–22), which was phosphorylated at the 5′ end but not at the 3′ end. The miR-16 levels are normalized against the RNU48 levels. Error bars indicate s.d. (n = 3). *, P<0.05. (B) Quantitation of the miR-16 level in HL60 cells with a LightCycler 480 SYBR Green I Kit. Total RNA was extracted from the HL60 cells that were cultured for 24 hours in the absence or presence of sgR16(1–14) or sgR16(1–22). sgR16(1–14) and sgR16(1–22) were phosphorylated at both 5′ and 3′ ends. The miR-16 levels are normalized against the 5S rRNA levels. Error bars indicate s.d. (n = 3). *, P<0.001. (C) Real-time PCR analysis for the Bcl-2 mRNA level in HL60 cells. Total RNA was extracted from the HL60 cells that were cultured for 24 hours in the absence or presence of sgR16(1–14) or sgR16(1–22). sgR16(1–14) and sgR16(1–22) were phosphorylated at both 5′ and 3′ ends. The Bcl-2 mRNA levels are normalized against the β-actin mRNA levels. Error bars indicate s.d. (n = 3). *, P<0.001.

https://doi.org/10.1371/journal.pone.0038496.g004

We also carried out a similar experiment with HL60 cells using 5′- and 3′-phosphorylated sgR16(1–14) and sgR16(1–22). Likewise sgR16(1–14) significantly reduced the miR-16 level to 53%, but in contrast sgR16(1–22) also did work almost perfectly (Figure 4B). This was also the case in HEK293 cells (data not shown). This discrepancy would be attributed to the phosphorylation at the 3′ end, which appears to make RNA more efficient in being taken up by human cells and/or more stable in the cells than RNA with no 3′-phosphate judging from a result of the RNA survivability test (data not shown).

Furthermore, to show that the knockdown of miR-16 is functional, we examined its endogenous target, the Bcl-2 mRNA, for the stability [30]. The Bcl-2 mRNA levels in HL60 cells were upregulated to 122% and 137% by downregulating the miR-16 levels by sgR16(1–14) and sgR16(1–22), respectively (Figure 4B,C). This result implies that sgR16(1–14) can stabilize the Bcl-2 mRNA by reducing the miR-16 level and subsequently inhibiting the mRNA transport to P-bodies.

Downregulation of miRNA Expression Levels by Naked 14-nt sgRNAs

We also examined three naked 14-nt sgRNAs against miR-142-3p, miR-206, and miR-19a/b for their guiding ability. sgR142(1–14) significantly reduced the miR-142-3p level to 48% and 47% in HL60 and DAUDI cells, respectively, without any transfection reagents, whereas sgR142(1–23) decreased the level slightly in both cell lines (Figure 5A). The 22-nt 5′- and 3′-phosphorylated sgR16(1–22) worked very efficiently even in a naked form (Figure 4B), whereas the 23-nt sgR142(1–23), which was also 5′- and 3′-phosphorylated, barely worked, suggesting that, unlike 14-nt sgRNAs, the efficiency of naked 22–23-nt RNAs in being taken up by living cells and/or their stability in the cells may change depending on their sequence itself as well as 3′-phosphorylation status.

thumbnail
Figure 5. Downregulation of miRNA expression levels by naked 14-nt sgRNAs.

(A) Real-time PCR analyses for miR-142-3p were carried out for total RNAs extracted from HL60 and DAUDI cells that were cultured for 24 hours in the absence or presence of sgR142(1–14) or sgR142(1–23). The miR-142-3p levels are normalized against the RNU48 levels. (B) Real-time PCR analysis for miR-206 was performed for total RNA extracted from C2C12 cells that were cultured for 24 hours in the absence or presence of sgR206(1–14). The miR-206 levels are normalized against the sno234 RNA levels. (C) Real-time PCR analysis for miR-19a/b was performed for total RNA extracted from RPMI-8226 cells that were cultured for 24 hours in the absence or presence of sgR19(1–14). The miR-19a/b levels are normalized against the 5S rRNA levels. Error bars indicate s.d. (n = 3). *, P<0.05; **, P<0.001.

https://doi.org/10.1371/journal.pone.0038496.g005

The miR-206 expression in C2C12 cells was efficiently downregulated to 22% by sgR206(1–14), and the miR-19a/b level in RPMI-8226 cells was reduced to 28% by sgR19(1–14) (Figure 5B,C). These observations imply that in general we can eliminate a specific cellular miRNA at least by ∼50% by using 1 µM of a naked 14-nt sgRNA on the basis of TRUE gene silencing.

miRNA-targeting RNA Therapy

Our results suggest that TRUE gene silencing can be used for RNA therapy targeting disease-causing miRNA. miRNAs to be targeted would include miR-19a/b and miR-21 for cancer therapy and miR-122 for hypercholesterolemia and hepatitis C treatments. As 14-nt sgRNA can be taken up easily by the cells without any carrier reagents such as cholesterol and cationic liposome, and can guide tRNase ZL to cleave miRNA, TRUE gene silencing may be advantageous over a technology based on the inhibitory mechanism through binding and sequestering [20][22].

Supporting Information

Figure S1.

The reduction in the miR-16 level by sgR16(1–14) is attributable at least partly to tRNase ZL. (A) Quantitation of the miR-16 level in HEK293 cells with a LightCycler 480 SYBR Green I Kit. The HEK293 cells were transfected with mock, 35 nM of sgR16(1–14) or sgR16(1–22) together with mock or the anti-tRNase-ZL siRNA. sgR16(1–14) and sgR16(1–22) were phosphorylated at both 5′ and 3′ ends. The miR-16 levels are normalized against the 5S rRNA levels. Error bars indicate s.d. (n = 3). *, P<0.001. (B) Western blot analysis. The tRNase ZL level under the above transfection conditions was analyzed. β-actin was used as a loading control.

https://doi.org/10.1371/journal.pone.0038496.s001

(PDF)

Figure S2.

Naked 14-nt sgRNA can be taken up by living cells. (A) Confocal laser microscopic images of HeLa cells. HeLa cells were fixed and stained with ethidium bromide 24 hours after the cells were cultured in the absence or presence of 1 µM of the naked 14-nt 3′-FITC-labeled sgRNA14. (B) Fluorescence ratiometric analysis. Fluorescence ratiometric images of HeLa, HEK293, and Jurkat cells were taken 24 hours after the cells were cultured in media containing 1 µM of the 3′-FITC-labeled sgRNA14. (C) sgRNA survivability tests. The 3′-FITC-labeled sgRNA14 was analyzed on a denaturing 20% polyacrylamide gel. The standard 3′-FITC-labeled sgRNA14 (S) and the sgRNA14 retrieved from inside the cells (R) are shown. Asterisks denote the recovered sgRNA. The bands shifted upward would correspond to complexes between the sgRNA and small cellular RNAs.

https://doi.org/10.1371/journal.pone.0038496.s002

(PDF)

Text S1.

Supplementary Materials and Methods.

https://doi.org/10.1371/journal.pone.0038496.s003

(PDF)

Author Contributions

Conceived and designed the experiments: RAE MN. Performed the experiments: M. Takahashi RAE MA MS M. Tamura. Analyzed the data: M. Takahashi RAE TY YY M. Tamura MN. Wrote the paper: MN.

References

  1. 1. Nashimoto M (1997) Distribution of both lengths and 5′ terminal nucleotides of mammalian pre-tRNA 3′ trailers reflects properties of 3′ processing endoribonuclease. Nucleic Acids Res 25: 1148–1155.
  2. 2. Takaku H, Minagawa A, Masamichi T, Nashimoto M (2003) A candidate prostate cancer susceptibility gene encodes tRNA 3′ processing endoriobonuclease. Nucleic Acids Res 31: 2272–2278.
  3. 3. Elbarbary RA, Takaku H, Uchiumi N, Tamiya H, Abe M, et al. (2009) Modulation of gene expression by human cytosolic tRNase ZL through 5′-half-tRNA. PLoS ONE 4: e5908.
  4. 4. Elbarbary RA, Takaku H, Uchiumi N, Tamiya H, Abe M, et al. (2009) Human cytosolic tRNase ZL can downregulate gene expression through miRNA. FEBS Lett 583: 3241–3246.
  5. 5. Tamura M, Nashimoto C, Miyake N, Daikuhara Y, Ochi K, et al. (2003) Intracellular mRNA cleavage by 3′ tRNase under the direction of 2′-O-methyl RNA heptamers. Nucleic Acids Res 31: 4354–4360.
  6. 6. Habu Y, Miyano-Kurosaki N, Kitano M, Endo Y, Yukita M, et al. (2005) Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL. Nucleic Acids Res 33: 235–243.
  7. 7. Nakashima A, Takaku H, Shibata HS, Negishi Y, Takagi M, et al. (2007) Gene-silencing by the tRNA maturase tRNase ZL under the direction of small guide RNA. Gene Therapy 14: 78–85.
  8. 8. Elbarbary RA, Takaku H, Tamura M, Nashimoto M (2009) Inhibition of vascular endothelial growth factor expression by TRUE gene silencing. Biochem and Biophys Res Commun 379: 924–927.
  9. 9. Sano T, Takahashi M, Nozaki T, Takahashi Y, Tamura M, et al. (2011) Expanding the utility of heptamer-type sgRNA for TRUE gene silencing. Biochem and Biophys Res Commun 416: 427–432.
  10. 10. Nashimoto M (1995) Conversion of mammalian tRNA 3′ processing endoribonuclease to four-base-recognizing RNA cutters. Nucleic Acids Res 23: 3642–3647.
  11. 11. Nashimoto M (1996) Specific cleavage of target RNAs from HIV-1 with 5′ half tRNA by mammalian tRNA 3′ processing endoribonuclease. RNA 2: 2523–2524.
  12. 12. Nashimoto M, Geary S, Tamura M, Kasper R (1998) RNA heptamers that directs RNA cleavage by mammalian tRNA 3′ processing endoribonuclease. Nucleic Acids Res 26: 2565–2571.
  13. 13. Nashimoto M (2000) Anomalous RNA substrates for mammalian tRNA 3′ processing endoribonuclease. FEBS Lett 472: 179–186.
  14. 14. Takaku H, Minagawa A, Takagi M, Nashimoto M (2004) The N-terminal half-domain of the long form of tRNase Z is required for the RNase 65 activity. Nucleic Acids Res 32: 4429–4438.
  15. 15. Takaku H, Minagawa A, Takagi M, Nashimoto M (2004) A novel four-base-recognizing RNA cutter that can remove the single 3′ terminal nucleotides from RNA molecules. Nucleic Acids Res 32: e91.
  16. 16. Shibata HS, Takaku H, Takagi M, Nashimoto M (2005) The T loop structure is dispensable for substrate recognition by tRNase ZL. J Biol Chem 280: 22326–22334.
  17. 17. Sayed D, Abdellatif M (2011) MicroRNAs in development and disease. Physiol Rev 91: 827–887.
  18. 18. Aqeilan RI, Calin GA, Croce CM (2010) miR-15a and miR-16–1 in cancer: discovery, function and future perspectives. Cell Death Differ 17: 215–220.
  19. 19. Cho WC (2007) OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer 6: 60.
  20. 20. Pichiorri F, Suh SS, Ladetto M, Kuehl M, Palumbo T, et al. (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 105: 12885–12890.
  21. 21. Elmén J, Lindow M, Schütz S, Lawrence M, Petri A, et al. (2008) LNA-mediated microRNA silencing in non-human primates. Nature 452: 896–899.
  22. 22. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, et al. (2010) Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science 327: 198–201.
  23. 23. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59–74.
  24. 24. Scherer WF, Syverton JT, Gey GO (1953) Studies on the propagation in vitro of poliomyelitis viruses. IV. Viral multiplication in a stable strain of human malignant epithelial cells (strain HeLa) derived from an epidermoid carcinoma of the cervix. J Exp Med 97: 695–710.
  25. 25. Schneider U, Schwenk H, Bornkamm G (1977) Characterization of EBV-genome negative “null” and “T” cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma Int J Cancer 19: 621–626.
  26. 26. Gallagher R, Collins S, Trujillo J, McCredie K, Ahearn M, et al. (1979) Characterization of the continuous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 54: 713–733.
  27. 27. Yaffe D, Saxel O (1977) Serial passaging and differentiation of myogenic cells isolated from dystrophic mouse muscle. Nature 270: 725–727.
  28. 28. Matsuoka Y, Moore GE, Yagi Y, Pressman D (1967) Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 125: 1246–1250.
  29. 29. Nashimoto M, Tamura M, Kaspar RL (1999) Selection of cleavage site by mammalian tRNA 3′ processing endoribonuclease. J Mol Biol 287: 727–740.
  30. 30. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944–13949.